Initiation of prolyl cis-trans isomerisation in the CDR-H3 loop of an antibody in response to antigen binding

Keiko Shinoda & Hideaki Fujitani

Proline cis-trans isomerisation is a regulatory mechanism used in a range of biological processes, and is related to various diseases such as Alzheimer's disease and cancer. However, the details of the exact molecular mechanism by which it occurs are not known. Using X-ray crystallography, proline isomerisation has been shown to occur following formation of an antigen-antibody complex between the target epiregulin (EPR) and the antibody 9E5, at proline (Pro103), located in the third complementarity-determining region (CDR) of the heavy chain of 9E5. To obtain an accurate description of the pathway involved in cis-trans isomerisation in this system, we performed ten independent long molecular dynamics (MD) simulations starting at a stable transient bound structure obtained from many short binding MD simulations. As a result, we were able to describe the process by which cis-trans isomerisation is initiated, and suggest a catalysis mechanism for cis-trans isomerization in this antigen-antibody system. We found that Asp102, which is immediately adjacent to Pro103, rotates while changing its interacting partner residues in the light chain of 9E5, and at the same time EPR polar residues help to stabilise the intermediate states in the isomerisation process by interacting strongly with Asp102.

Among the 20 amino acids, proline is unique because both the cis and trans conformers of the prolyl peptide bond are thermodynamically feasible, in contrast to non-prolyl peptide bonds that strongly favour remaining in the trans conformation. Because proline can convert between the cis and trans conformers, it has been shown to function as a molecular timer or switch. This prolyl cis-trans isomerisation or “proline switch” is known to be an effective regulatory mechanism in a wide range of biological processes including cell signalling, ion channel gating, neurodegeneration, gene expression, and others. Anomalies in these control mechanisms have been suggested to be related to various diseases such as Alzheimer’s disease and cancer. Because prolyl cis-trans isomerisation involves rotation around the prolyl peptide bond (i.e. the C-N bond), which is a partial double bond, this requires a high activation energy (approximately 20 kcal/mol). As a result, cis-trans isomerisation is a slow process occurring over seconds to minutes. Cis-trans peptidyl prolyl isomerases (PPIases) are a class of enzymes that catalyse prolyl cis-trans isomerisation to reduce the isomerisation time roughly by 10^5 times. Three families of PPIases have been identified: Cyclosporin A binding cyclophilins, such as cyclophilin A (CypA), FK506 binding proteins (FKBPs), such as FKBP12, and parvulin-like PPIases, such as Pin1. Many studies have been performed to elucidate the catalytic mechanism of PPIases, including not only experimental studies, but also computational studies with free energy calculations using either standard molecular dynamic (MD) simulations, QM/MM or accelerating MD simulations such as metadynamics, which use a time-dependent biasing potential acting on certain prechosen chemical reaction coordinates. In general, there is a consensus that acceleration of the cis-trans isomerisation rate by PPIases occurs by a catalytic mechanism in which the substrate is stabilized in its transition state. However, the details of the mechanism at the atomic level still remain to be clarified.

Recently, using X-ray crystallography, cis-trans isomerisation was found to occur upon binding of an antibody (9E5) to epiregulin (EPR). Epiregulin is a member of the epidermal growth factor (EGF) family that, upon
binding to the EGF receptor (EGFR), stimulates proliferative signalling in cancer cells. 9E5 is an anti-EPR antibody that inhibits EGFR signalling by EPR but not by EGF. The antigen-binding site of the antibody is formed by six loops referred to as complementary determining regions (CDR), with three (L1, L2, and L3) from the light chain variable domain (VL), and three (H1, H2, and H3) from the heavy chain variable domain (VH). Among the loops, the CDR-H3 loop plays a distinctive role in antigen recognition. Kado et al. found that prolyl cis-trans isomerisation occurred in the CDR-H3 loop (Arg98-Gly99-Gly100-Gly101-Asp102-Pro103-Val104-Phe105-Val106-Tyr107-Trp108) of the fragment antigen-binding portion (Fab) of 9E5 in the X-ray crystal structure. The 9E5 Fab has a proline at residue 103 (Pro103) in the CDR-H3 loop, which was found to be in the cis conformation for EPR-free apo 9E5 and in the trans conformation in the EPR-9E5 complex. To the best of our knowledge, this is the first example of a proline cis-trans conformation change occurring in the CDR loop following antigen-antibody binding.

In this study, we performed extensive MD simulations to investigate the mechanism of peptidyl prolyl cis-trans isomerization of the antigen-antibody complex of EPR and 9E5, which was intensively explored for use in cancer therapy.

Results and Discussion

A stable cis-complex was obtained from 964 independent 200 ns binding MD simulations followed by long MD simulations. To obtain the structure of EPR bound to 9E5 in its apo form and for possible comparison with experimental data by surface plasmon resonance (SPR), we performed 964 independent 200 ns binding MD simulations. We were able to obtain the structures of many complexes between EPR and apo 9E5. Figure 1 shows the EPR centre of mass (COM) on the 9E5 surface at 200 ns. The COMs of the EPR are classified by the interaction energy between EPR and 9E5, which is represented by different colours and circle sizes. At 200 ns, the EPRs were found over a wide region of 9E5, i.e. not only around the CDR region, but also around the constant region of 9E5. This indicates that a time of 200 ns is too short for all EPRs to settle to proper positions. For example, the EPR bound at the constant region of the 9E5 Fab had the lowest interaction energy (averaged over the period of 170 to 200 ns) of $-877 \text{ kJ/mol}$. However, the interaction energy of this system was not yet stable, and after additional 2 $\mu$s MD simulations, the interaction energy decreased by more than 300 kJ/mol compared with the interaction energy at 200 ns. (Supplementary Fig. S1)

We compared the 964 structures at 200 ns to the x-ray crystal structure, using a similarity score (see Eq. 1 in the Methods section) to select a bound structure. Based on this similarity score, the structure most closely resembling the crystal structure had a score of 0.24. This structure had an interaction energy between the EPR and 9E5 of $-584 \text{ kJ/mol}$ and was compared to the crystal structure in Fig. 1 (top right). The two structures are similar but have important differences. The main differences are in the CDR-H3 loops and the conformation of Arg40 in EPR. Arg40 in EPR does not form a contact with 9E5 in the highest-score structure, whereas it forms hydrogen bonds with Asp52 and Lys30 in the VH in the crystal structure.

To examine the stability of the highest-score structure in the EPR-apo 9E5 complex, we performed an additional ten independent 2 $\mu$s MD simulations using the highest-score structure as the initial configuration. After approximately 1 $\mu$s, a bound structure highly similar to the x-ray crystal structure was observed (score = 0.15) in one of the ten simulations. Arg40, which was not found to interact with 9E5 at 200 ns, formed hydrogen bonds with the CDR of 9E5 (specifically at residues Asp52 and Asp31). The interaction energy of this complex between EPR and 9E5 was $-1087 \text{ kJ/mol}$ (averaged over the period of 1.9 to 2.0 $\mu$s), which is lower than that of the highest-score structure by more than 400 kJ/mol. This stable complex between EPR and apo 9E5 is hereafter referred to as the cis-complex.

To examine the stability of the cis-complex, we conducted an additional ten independent 8 $\mu$s-MD simulations using the cis-complex structure at 2 $\mu$s as the initial configuration. All of the ten trajectories were very stable for 1 $\mu$s and then showed small differences (see later subsections). For comparison with the cis-complex, we conducted 3 $\mu$s MD simulations starting from the complex crystal structure with trans Pro103, which is referred to as the trans-complex.

Asp102 is a key residue in 9E5, and EPR also plays an important role in the CDR-H3 loop conformational change from the cis-complex to the trans-complex. Figure 2 shows close-up views of typical CDR-H3 loop structures for the cis-complex and the trans-complex obtained from the 3 $\mu$s MD simulations. Conformational differences can be clearly observed in the CDR-H3 loop region; these differences arise as a result of the respective cis and trans conformations of Pro103 in the loop. In addition, the interactions of Asp102, which is adjacent to Pro103, differ between the cis-complex and the trans-complex. In the cis-complex, Asp102 protrudes toward EPR and interacts with several residues in EPR, forming hydrogen bonds with them. In the trans-complex, Asp102 turns toward the base of the CDR-H3 loop and forms hydrogen bonds with Arg98 and Gly99.

We also note a difference at the bottom of the backside of the CDR-H3 loop. As shown in Fig. 2C, in the trans-complex, the distance between Asp61 in the VH and Arg95 in the VL was greater than that in the cis-complex. The minimum distances were 0.49 $\pm$ 0.008 nm for the trans-complex and 0.43 $\pm$ 0.001 nm for the cis-complex. In addition, Asp61 and Arg95 in the trans-complex do not interact with each other. However, in the case of the cis-complex, there is a very slight repulsive interaction that arises mainly from the oxygen atoms in Asp61 (OD1 and OD2) and the backbone oxygen in Arg95.

Examining the overall structure, we found that the distance between EPR and 9E5 in the cis-complex was slightly larger than that in the trans-complex (the distance between the centre of mass of EPR and that of the Fv fragment of 9E5 was 2.43 $\pm$ 0.008 nm for the trans-complex, and 2.47 $\pm$ 0.005 nm for the cis-complex). In Fig. 2B, in the cis-complex, Ser26 in EPR interacts with Thr53 in the VL, whereas, in the trans-complex, Ser26 interacts with His49 and His55 in the VL located below Thr53; this was also shown by the x-ray crystallography analysis.
These results imply that during isomerisation, VH and VL change their conformations such that the repulsive interaction between them disappears.

Next, we conducted a detailed analysis of the interaction energies, comparing the cis-complex with the trans-complex, to determine how the interaction energy changes from the transient structure (i.e. the cis-complex) to the final EPR-bound structure (i.e. the trans-complex). Figure 3 shows a breakdown of the interaction energies between each residue in EPR and the entire 9E5 molecule (A) and between each residue in 9E5 and the entire EPR molecule (B). Our previous study revealed three interaction regions in the EPR-9E5 bound structure (trans-complex) obtained from a breakdown of the interaction energies between each residue in EPR and the whole 9E5 molecule. These regions were interaction-1, in which the main interaction is between Asp9 in EPR and Arg50 in VH or Arg95 in VL; interaction-2, in which the main interaction is between Arg40 in EPR and Asp31 and Asp52 in VH; and interaction-3, in which the main interaction is between EPR and the CDR-H3 loop. Among these interactions, interaction-1 was the strongest, and interaction-2 were the next strongest.

These three regions of interaction were also found in the cis-complex as shown in Fig. 3(A), but large differences were noted for all three interactions. First, although the interaction energy between Asp9 in EPR and 9E5 is almost the same in both complexes, the mode of interaction is different. Asp9 interacts with two arginine residues, Arg50 in VH and Arg95 in VL, which are positioned on both sides of Asp9. However, as the direction of the three oxygen atoms (OD1, OD2, and the carbonyl oxygen) in Asp9 is different in both complexes, the main interactions seen for Asp 9 are different. In particular, in the cis-complex, the OD1 and OD2 atoms interact with the guanidinium hydrogen atoms in Arg50, whereas in the trans-complex, the OD1 and OD2 atoms mainly interact with Arg95. Therefore, Asp9 interacts more strongly with Arg50 than with Arg95 in the cis-complex, and
vice versa for the trans-complex. In addition, Asp9 in the cis-complex also interacts with Lys59 in the VH. In the trans-complex, Ser7 in EPR interacts mainly with Tyr91 in VL, and Ser8 in EPR interacts mainly with Asp92 in VL, whereas in the cis-complex, both Ser7 and Ser8 interact mainly with Asp92 in VL.

Second, in the trans-complex, Arg40 and Glu42 in EPR have a stronger interaction with the whole 9E5 molecule than that observed in the cis-complex. In the trans-complex but not in the cis-complex, Glu42 in EPR interacts mainly with Lys30 in VH. Third, in the cis-complex, Ser8, Asn11, Tyr21, and Asn28 in EPR strongly interact with the whole 9E5 molecule to a greater extent than in the trans-complex. As shown in Fig. 3(B), three residues (Asn11, Tyr21, and Asn28) among the five residues interact mainly with Asp102 in VH. The interaction energy

Figure 2. Structural comparison of the CDR-H3 loops and the interface between the heavy and light chains for both the trans-complex and the cis-complex. (A) Structures of the trans-complex and the cis-complex. The heavy chain, light chain, and EPR are coloured cyan, magenta, and green for the cis-complex and blue, red, and dark green for the trans-complex, respectively. (B) Magnified views of the CDR-H3 loop structures for the trans-complex and cis-complex. The CDR-H3 loop is shown in red. The heavy chain, light chain, and EPR are coloured cyan, magenta, and green, respectively. Hydrogen bonds are shown as orange dashed lines. (C) Close-up view of the backside of the CDR-H3 loop and the interface between the heavy chain and the light chain. The distance between Arg95 in the light chain and Asp61 in the heavy chain for the trans-complex is slightly longer than that in the cis-complex, and is represented as black circles. Residues are represented using the one-letter code for amino acids.
contributed by Asp102 is very different in both complexes. In the trans-complex, Asp102 interacts strongly with Arg98, which is located in the base of the CDR-H3 loop. However, in the cis-complex, Asp102 interacts with Asn11, Tyr21, Ser26, Gln27, and particularly Asn28 in EPR. This indicates that the dominant mode of interaction for Asp102 changes from an inter-molecular interaction (cis-complex) to an intra-molecular interaction (trans-complex). From these data, it is clear that Asp102 plays a key role in cis-trans isomerisation.

10 μs-MD simulations of the cis-complex reveal changes in the omega angle of Pro103. Figure 4 shows changes in the CDR-H3 loop structure and interaction energy of the ten trajectories over time during the 8 μs MD simulations. The cis-complex over nine trajectories displayed a remarkable conformational stability during the simulations. One trajectory shown in purple revealed that the bound structure underwent a change (score = 0.36), although EPR binding was maintained as described below.

To monitor conformational changes in Pro103 directly, we calculated the ω (omega) dihedral angle of Pro103, which involves the backbone atoms Cα–C–N–Cα. Generally, for the free X-Pro isomer, the ω angle will fluctuate around the centre, being close to either 0° or 180°, corresponding to the cis or trans configuration at equilibrium. However, in our system this was not the case. In apo 9E5, the ω angle of Pro103 (cis conformer) was found to be distributed around −12° because the C-N bond of Pro103 was twisted in a negative direction due to the strong interaction between Asp102 or Gly101 in VH and His49 in VL (Supplementary Fig. S2). However, in the cis-complex, rather than His49, EPR largely interacted with Asp102 and Gly101 in VH, and the distribution of the ω angle was shifted in a positive direction as a result of the interaction; the ω angle was found to be distributed around approximately −4°.

The distribution of the ω dihedral angle is shown for the same interval time of 1 μs in Fig. 4 (top). For the interval from 3 to 4 μs, and from 5 to 6 μs, the ω angles of Pro103 in the ten simulations were distributed in the same way. However, over the time interval of 7 to 8 μs, the distributions in the ten simulations were slightly dispersed. For the time interval from 9 to 10 μs, the distributions of the ω angle of two trajectories, shown as purple and green in Fig. 4, markedly shifted in a positive or negative direction, respectively.

The purple trajectory had a change in binding structure after approximately 6.5 μs, such that the hydrogen bond between Arg40 in EPR and Asp31 and Lys30 in 9E5 was disrupted, while at the same time maintaining interaction-1 (Supplementary Fig. S3). In the process, the hydrogen bonds between Arg40 and 9E5 (Asp31 and
Lys30) were disrupted, and we observed that the hydrogen bonds broke immediately after Gly101 interacted with His49. The interaction of Gly101 with His49 was observed in apo 9E5. The distribution of the $\omega$ angle gradually shifted to be more negative at longer times after 6.5 $\mu$s, with an average $\omega$ angle of $-14.8^\circ$ for the time interval from 9 to 10 $\mu$s. In contrast, only the green trajectory revealed that the $\omega$ distribution shifted to the positive side, with the average $\omega$ angle changing from $-6.3^\circ$ to $2.7^\circ$. This small positive $\omega$ angle implies that the green trajectory did not achieve the transition state for Pro103 required for isomerisation, as the transition state is characterized by a twist of 90 degrees in the $\omega$ angle of the prolyl peptide bond as has been reported in several previous studies. At 10 $\mu$s, several major conformational changes in the residues and changes in the interaction mode were observed in the green trajectory. Figure 5 shows a magnified image of the CDR-H3 loop at 10 $\mu$s for the green trajectory, and the dashed black lines indicate the newly formed hydrogen bonds between Asp102 and Tyr91 or His49 in VL. The interaction energies between Asp102 and Tyr91 or His49 at 10 $\mu$s were larger than those at 3 $\mu$s (Table 1). It was also observed that interactions between EPR and Asp102 increased at 10 $\mu$s (Table 1). Tyr13 in EPR also had large changes in its mode of interaction. From 9 to 10 $\mu$s, Tyr13 in EPR interacts with Gly99 and Arg98 in the CDR-H3 loop through hydrogen bonding, whereas Tyr13 interacts with Tyr33 in VH from 2 to 3 $\mu$s.

We performed an additional 10 $\mu$s MD simulation for the green trajectory (20 $\mu$s in total) to observe the change in the $\omega$ angle for a longer time. Greater interaction of EPR with 9E5 for the cis-complex reflects high association in the SPR experiment. Figure 4 (bottom) shows the time course of the interaction energies between EPR and 9E5 for the ten independent trajectories. During the period from 2 to 10 $\mu$s, with the exception of the purple trajectory, the total interaction energies between EPR and 9E5 for the cis-complex were lower than those for the trans-complex (dashed black line); on average, they were more than 100 kJ/mol lower. For the purple trajectory, the total interaction energy decreased mainly due to breakage of the hydrogen bond between Arg40 and 9E5. The average interaction energies from 2 to 10 $\mu$s between EPR and 9E5 were $-1015 \pm 18$ kJ/mol for the cis-complex (average of nine trajectories with omission of the purple trajectory) and $-846 \pm 8$ kJ/mol for the trans-complex, respectively (average of four trajectories). The reason why the interaction energy for the cis-complex was so much larger might be found in the different results obtained in the two previous experiments. The binding affinities for EPR with 9E5 (IgG) have been previously measured using two different methods, namely SPR and isothermal titration calorimetry (ITC). The equilibrium dissociation constant ($K_D$) obtained using SPR ($K_D = 0.86$ nM) was an order of magnitude stronger than that determined thermodynamically using ITC ($K_D = 6.5$ nM).

The ITC measurement by Kado et al. used a titration interval of approximately 2.5 minutes. Because SPR measures the mass of material binding to the sensor surface, the association rate constant ($K_a$) reflects the initial stage of binding process. The SPR kinetic analysis by Kado et al. showed that the calculated $K_a$ is dominated by the
high association rate constant, in which the \( K_D \) was calculated from\( K_D = \frac{k_{off}}{k_{on}} \). Therefore, it can be concluded that the large calculated interaction energy for the cis-complex gave the high association rate constant between ERP and 9E5.

The environment around the CDR-H3 loop is suitable for isomerisation. Previous computational studies of the cis-trans isomerisation in the PPIase system have shown that the substrate-binding sites of a protein (enzyme) in which isomerisation of the substrate occurs have two features, i.e. several polar residues leading to the C-N bond rotation of proline in the substrate, and a hydrophobic pocket for substrate association\(^2\). These electrostatic and hydrophobic features seen in the substrate-PPIase system can also be seen in the CDR-H3 loop of 9E5. In this case, Gly99-Gly100-Gly101-Asp102-Pro103 in the CDR-H3 loop correspond to the substrate for the PPIase. With respect to the polar residues around the CDR-H3 loop, there are several EPR residues that interact strongly with Asp102 in the cis-complex, as described above. A hydrophobic region, consisting of Val104, Phe105, Val106 in VH and Leu46 in VL, is located around the CDR-H3 loop and is represented as a grey surface in Fig. 5.

Two other factors also promote isomerisation in the present system: (1) Pro103 and Asp102 are confined in the loop structure, and (2) three consecutive glycines are present in the CDR-H3 loop. With respect to Pro103 and Asp102 in the loop structure, a relationship between loop form and an increase in the isomerisation rate was previously reported, in which the rate of cis-trans isomerisation of the \( \omega \) angle was enhanced by a factor of 10 by constraining the prolyl peptide bond in a loop conformation\(^5\). These studies suggest that conformational constraints by the loop form lead to increased conformational flexibility of the peptide backbone and lead to the conformation of the prolyl peptide in the transition state. Additionally, the three consecutive glycines present in the CDR-H3 loop make this region flexible. It has also been previously shown that the beta-hairpin loop, in which the Gly-Gly motif is constrained, provides increased flexibility of Gly-Gly and rapid isomerisation\(^4\).

Table 1. Main interaction energies with Asp102 in the green trajectory (kJ/mol). The interaction energies were calculated for 2.9 to 3.0 \( \mu \)s and for 9.9 to 10 \( \mu \)s respectively.
Interestingly, in our study, the fluctuation of Gly99 in the CDR-H3 loop was greater in the cis-complex than in apo 9E5 (Supplementary Fig. S4). Constraint of the CDR-H3 loop by EPR increases the flexibility of Gly99, and this increased flexibility would be convenient to increase the rate of Pro103 cis-trans isomerisation. From these data, it can be concluded that surrounding Pro103 in the CDR-H3 loop there is an environment that enables cis-trans isomerisation to occur much more rapidly compared to that in free X-Pro peptides.

**Catalysis mechanism for cis-trans isomerisation in the EPR-9E5 system.** Cis-trans isomerisation occurs through rotation of the C-N bond. There are two directions by which the C-N bond can be rotated: clockwise and anti-clockwise looking from the N-terminal to the C-terminal direction along the C-N bond. It should be noted that a positive omega angle corresponds to moving the N-terminal atom anti-clockwise or the C-terminal atom clockwise. However, in this case, the rotation of the C-N bond that occurs during isomerisation is in a predominately unidirectional fashion, i.e., in the direction that moves the N-terminal Cα atom of Asp102 anti-clockwise, because the residues that interact with Asp102 to help promote the isomerisation are not exposed to the solvent side, but rather are exposed to the inner side of 9E5. Therefore, the side chain of Asp102 can rotate more easily anti-clockwise (the omega angle being positive) than clockwise. As mentioned above, we observed a green trajectory that had a positive omega angle for Pro103 over the interval of 9 to 10 μs. The positive value was observed from approximately 8 to 14 μs during 20 μs (Supplementary Fig. S5).

Regarding Asp102, the charged residue Arg95 in VL is close to Tyr91, which is interacting with Asp102 (Fig. 5). From these data, we envision the cis-trans isomerisation process in the EPR-9E5 antibody system occurring as follows (Fig. 6): Asp102 interacting with Tyr91 and His49 at 10 μs next interacts with Arg95 in VL. Subsequently, the C-N bond of Pro103 rotates to allow binding of Asp102 to Arg98 in the CDR-H3 loop. This interaction involves guanidino groups in Arg98 forming hydrogen bonds with oxygen in Asp102, thus completing the isomerisation process. The time course of the minimum distance between the Asp102 and Arg95 in the green trajectory change was found to be correlated with the ω angle during 20 μs (Supplementary Fig. S5). The minimum distance was reduced from 0.7 at 2 μs to 0.5 nm at 10 μs as the ω angle of Pro103 shifted to the positive side. Arg95 may also facilitate rotation of the Pro103 peptide bond by stabilizing the transition state of the isomerisation. The role of Arg95 is therefore similar to that of the highly conserved Arg55 found in CypA 42,43, in which Arg55 in the substrate-binding site of CypA promotes isomerisation by weakening the double-bond character of the C-N bond by forming hydrogen bonds between the guanidino group in Arg55 and the carbonyl oxygen of the proline substrate.

From our data, we conclude that the EPR-9E5 structure seen in the green trajectory at 10 μs is in a stable intermediate state in over a microsecond time scale, leading to the transition state for isomerisation. This result implies that several stable intermediate states are adopted until isomerisation is complete, and the intermediate states are determined by the interactions between Asp102 and its surrounding residues. Thus, in this case isomerisation occurs by rotating Asp102 while changing the interacting partner residue in 9E5. At the same time, with respect to the increased interaction between EPR and Asp102 seen at 10 μs, EPR helps to stabilize the intermediate states during the isomerisation process. Thus, we consider that the VL and EPR cooperate to catalyse the cis-trans isomerisation of Pro103 like PPIase.

**Binding free energy and total free energy including conformation changes.** The cis-complex has lower binding free energy than the trans-complex because the interaction energies between EPR and 9E5 are favourable for the cis-complex, as explained in the previous subsections, and the fluctuation of the CDR-H3 loop was larger in the cis-complex (as shown in Supplementary Fig. S4). The larger fluctuation increases the entropy,
which is favourable for the binding free energy. The difference in binding free energy between the cis-complex and trans-complex was measured as the difference of the dissociation constants ($K_D$) between SPR and ITC.

The cis-complex is a transient state and the trans-complex is the final stable binding structure of EPR and 9E5. This means that the total free energy of the system should be favourable to the trans-complex. We expected some structural stress in the cis-complex. As mentioned in the previous section, there was a slight repulsive interaction between the residues in the VH-VL domain interface as shown in Fig. 2C. To clarify the detailed structural differences among the cis-complex, trans-complex and apo 9E5, we examined Ramachandran angles ($\phi$ and $\psi$) of all residues of 9E5 and analysed the angle distributions between 2 $\mu$s and 3 $\mu$s in the MD simulations. Excluding some residues near the binding region around the CDR, we found that several residues had different Ramachandran angle distributions. A typical such residue was Asn160 in heavy chain constant region 1 (CH1). This residue is located far from the binding region, but its conformation in the cis-complex differed from that in the trans-complex or apo 9E5, although the conformation of Asn160 was almost same between apo 9E5 and the trans-complex (Supplementary Fig. S6). It is not clear whether the conformational difference of Asn160 was related to an unfavourable total free energy of the cis-complex, but the conformation difference disappeared with the trans isomerisation of Pro103.

The interaction energy of the green trajectory changed near 15 $\mu$s in the MD simulation to be smaller than that of the trans-complex (Supplementary Fig. S7). This implies that the binding free energy would also be smaller. Finally, the cis-complex would change to a trans-complex having a lower total free energy. Considering that Pro103 is in a loop structure of the CDR-H3 including flexible consecutive glycines, we expected that the cis-trans isomerisation would occur on the order of hundreds of microseconds.

Methods

MD simulation. Figure 7 schematically shows the MD simulations that started from the free EPR and apo form 9E5 explained in the Results and Discussion section. For comparison, we conducted four 10 $\mu$s MD simulations for the EPR-9E5 complex (i.e. the trans-complex) and apo 9E5, in which the starting structures for the apo 9E5 and the trans-complex were taken from the x-ray crystal structures55. We also performed an additional 10 $\mu$s MD simulation for the green trajectory (20 $\mu$s in total) mentioned in the previous subsection.

Simulations of EPR binding to apo 9E5 (binding MD simulations) were performed by placing EPR at a minimum distance of 0.9 nm from the CDR of apo 9E5. Na$^+$ and Cl$^-$ ions were then added to make a neutral solution of 0.15 M. After energy minimization, the heavy atoms in the protein were restrained for 200 ps using a harmonic potential with a force constant of 1000 kJ$^{-1}$nm$^{-2}$ to relax the water molecules. Subsequently, MD simulations were performed under isotropic isothermal-isobaric (NPT) conditions. MD simulations were conducted with different initial velocities assigned to each atom of the simulation system from a Boltzmann distribution. A Nosé-Hoover thermostat62,63 was used to keep the temperature at 298 K, with a relaxation time of 1 ps. A Parrinello-Rahman barostat64,65 was used to isotropically regulate the pressure at 1 atm, with a relaxation time of 1 ps. The simulation time step was 4 fs and a virtual site model was adopted to remove the bond-angle degrees of freedom from hydrogen atoms. The leap-frog algorithm for integrating the equations of motion and the particle mesh and the Ewald (PME) method66,67 for calculating electrostatic interactions with a real-space cutoff of 1.0 nm were used. The neighbour list cut-off was set to 1.0 nm. The Lennard-Jones potential was smoothly switched to zero over the range of 0.8–0.9 nm. All bond lengths for proteins were constrained using the LINCS algorithm68. The atomic coordinates were saved every 5000 steps (20 ps) for analysis. All-atom MD simulations described in this study were performed using GROMACS version 4.6.5 (for the 964 MD binding simulations) and version 4.6.7 (for long-term simulations)99 with Fuji force field90 for proteins, AMBER models for ions and TIP3P for water101.

Similarity analysis. To select a bound structure similar to the x-ray crystal structure from the many complexes obtained at 200 ns, we analysed the similarity to the x-ray crystal structure, using a similarity score defined by

$$\text{score} = \frac{\sum_{\text{pair} \in \text{complex}} \left( \frac{\text{pair} - \text{crystal}}{N_{\text{pairs}}} \right)^2}{N_{\text{pairs}}}$$

(1)
where $r_{\text{pair}}$ represents the minimum distance between an EPR residue and a 9E5 residue of a pair for the bound structure from binding simulations, and $r_{\text{crystal}}$ represents that of the crystal structure. The residue pairs used for the score calculations were taken from Table 2 of Kado et al. The total number of selected residue pairs ($N_{\text{pair}}$) was 19.

**Data Availability.** The datasets generated and analysed during the current study are available from the corresponding author on reasonable request.

**References**

1. Fischer, G. Peptidyl-prolyl cis/trans isomerases and their effectors. *Angewandte Chemie International Edition* 33, 1415–1436 (1994).

2. Ladani, S. T., Soufrant, M. G., Barman, A. & Hamelberg, D. Computational perspective and evaluation of plausible catalytic mechanisms of peptidyl-prolyl cis–trans isomerases. *BBA General Subjects* 1850, 1994–2004 (2015).

3. Nath, P. R. & Isakov, N. Insights into peptidyl-prolyl cis–trans isomerase structure and function in immunocytes. *Immunology Letters* 163, 120–131 (2015).

4. Schmidpeter, P. A., Koch, J. R. & Schmid, F. X. Control of protein function by prolyl isomerization. *BBA General Subjects* 1850, 1973–1982 (2015).

5. Nicholson, L. K. & Lu, K. P. Prolyl cis-trans isomerization as a molecular timer in Crk signaling. *Molecular cell* 25, 483–485 (2007).

6. Sarkar, P., Saleh, T., Tseng, S.-R., Birge, R. B. & Kalodimos, C. G. Structural basis for regulation of the Crk signaling protein by a proline switch. *Nature Chemical Biology* 7, 51–57 (2011).

7. Sarkar, P., Reichman, C., Saleh, T., Birge, R. B. & Kalodimos, C. G. Proline cis-trans isomerization controls autoinhibition of a signaling protein. *Molecular Cell* 25, 413–426 (2007).

8. Wulf, G., Finn, G., Suizu, F. & Lu, K. P. Phosphorylation-specific prolyl isomerization: is there an underlying theme? *Nature Reviews Molecular Cell Biology* 7, 435–441 (2005).

9. Brajin, K. N., Mallis, R. J., Fulton, D. B. & Andreotti, A. H. Regulation of the tyrosine kinase tki by the peptidyl-prolyl isomerase cyclophilin A. *Proceedings of the National Academy of Sciences* 99, 1899–1904 (2002).

10. Xia, J. & Levy, R. M. Molecular dynamics of the proline switch and its role in Crk signaling. *Journal of Physical Chemistry B* 118, 4535–4545 (2014).

11. Lu, K. P., Finn, G., Lee, T. H. & Nicholson, L. K. Prolyl cis-trans isomerization as a molecular timer. *Nature Chemical Biology* 3, 619–629 (2007).

12. Mino, L., Fulton, D. B. & Andreotti, A. H. A case study of proline isomerization in cell signaling. *Front Bioioc* 18, 385–397 (2005).

13. Lu, K. P., Liu, Y.-C. & Zhou, X. Z. Pinning down proline-directed phosphorylation signaling. *Trends in Cell Biology* 12, 164–172 (2002).

14. Lu, K. P. & Zhou, X. Z. The prolyl isomerase PIN1: a pivotal new twist in phosphorylation signalling and disease. *Nature Reviews Molecular Cell Biology* 8, 904–916 (2007).

15. Yeh, E. et al. A signalling pathway controlling c-Myc degradation that impacts oncogenic transformation of human cells. *Nature Cell Biology* 6, 308–318 (2004).

16. Lumannis, S. C. et al. Cis–trans isomerization at a proline opens the pore of a neurotransmitter-gated ion channel. *Nature* 438, 248–252 (2005).

17. Melis, C., Bussi, G., Lumnis, S. C. & Molteni, G. Trans-cis switching mechanisms in proline analogues and their relevance for the gating of the 5-HT3 receptor. *Journal of Physical Chemistry B* 113, 12148–12153 (2009).

18. Pastorio, L. et al. The prolyl isomerase Pin1 regulates amyloid precursor protein processing and amyloid-β production. *Nature* 440, 528–534 (2006).

19. Wu, X. et al. The Ess1 prolyl isomerase is linked to chromatin remodeling complexes and the general transcription machinery. *EMBO Journal* 19, 3727–3738 (2000).

20. Nelson, C. J., Santos-Rosa, H. & Kozarides, T. Proline isomerization of histone h3 regulates lysine methylation and gene expression. *Cell* 126, 905–916 (2006).

21. Eckert, B., Martin, A., Balbach, J. & Schmid, F. X. Prolyl isomerization as a molecular timer in phage infection. *Nature Structural Molecular Biology* 12, 619–623 (2005).

22. Mantovani, F., Zannini, A., Rustighi, A. & De Sal, G. Interaction of p53 with prolyl isomerases: Healthy and unhealthy relationships. *BBA General Subjects* 1850, 2048–2060 (2015).

23. Wang, L. et al. A conserved proline switch on the ribosome facilitates the recruitment and binding of trIPases. *Nature Structural Molecular Biology* 19, 403–410 (2012).

24. Vogel, M., Bukan, B. & Mayer, M. P. AllostERIC regulation of Hsp70 chaperones by a proline switch. *Molecular Cell* 21, 359–367 (2006).

25. Takahashi, K., Uchida, C., Shin, R.-W., Shimazaki, K. & Uchida, T. Prolyl isomerase, Pin1: new findings of post-translational modifications and physiological substrates in cancer, asthma and alzheimer’s disease. *Cellular and Molecular Life Sciences* 65, 359–375 (2008).

26. Suzu, F., Ryo, A., Wulf, G., Lim, J. & Lu, K. P. Pin1 regulates centrosome duplication, and its overexpression induces centrosome amplification, chromosome instability, and oncogenesis. *Molecular and Cellular Biology* 26, 1463–1479 (2006).

27. Eakin, C. M., Berman, A. J. & Miranker, A. D. A native to amyloidoGenic transition regulated by a backbon e trigger. *Nature Structural Molecular Biology* 13, 202–208 (2006).

28. Torbee, V. Y. & Hilvert, D. Both the cis-trans equilibrium and isomerization dynamics of a single proline amide modulate β-2-microglobulin amyloid assembly. *Proceedings of the National Academy of Sciences* 110, 20051–20056 (2013).

29. Deb, S. et al. Complete thermodynamic and kinetic characterization of the isomer-specific interaction between Pin1-WW domain and the amyloid precursor protein cytoplasmic tail phosphorylated at Thr668. *Biochemistry* 51, 8583–8596 (2012).

30. Cheng, H. & Bovey, F. Cis-trans equilibrium and kinetic studies of acetyl-ll-proline and glycyl-l-proline. *Biopolymers* 16, 1465–1472 (1977).

31. Grasswolh, C. & Wüthrich, K. NMR studies of the rates of proline cis–trans isomerization of oligopeptides. *Biopolymers* 20, 2623–2633 (1981).

32. Schmid, F. X. & Baldwin, R. L. Acid catalysis of the formation of the slow-folding species of mase A: evidence that the reaction is prolyl isomerization. *Proceedings of the National Academy of Sciences* 75, 4764–4768 (1978).

33. Brandts, J. F., Halvorson, H. R. & Brennan, M. Consideration of the possibility that the slow step in protein denaturation reactions is due to cis-trans isomerism of proline residues. *Biochemistry* 14, 4953–4963 (1975).

34. Kofron, J. L., Kuzmic, P., Kishore, V., Colon-Bonilla, E. & Rich, D. H. Determination of kinetic constants for peptidyl prolyl cis-trans isomerases by an improved spectrophotometric assay. *Biochemistry* 30, 6127–6134 (1991).

35. Kern, D., Kern, G., Scherer, G., Fischer, G. & Drakenberg, T. Kinetic analysis of cyclophilin-catalyzed prolyl cis-trans isomerization by dynamic NMR spectroscopy. *Biochemistry* 34, 13594–13602 (1995).

36. Orozco, M., Tirado-Rives, J. & Jörgensen, W. L. Mechanism for the rotamase activity of FK506 binding protein from molecular dynamics simulations. *Biochemistry* 32, 12864–12874 (1993).
37. Trzesniak, D. & Van Gunsteren, W. F. Catalytic mechanism of cyclophilin as observed in molecular dynamics simulations: Pathway prediction and reconciliation of X-ray crystallographic and NMR solution data. Protein Science 15, 2544–2551 (2006).
38. Barman, A. & Hamelberg, D. Cysteine-mediated dynamic hydrogen-bonding network in the active site of Pn1l. Biochemistry 53, 3839–3850 (2014).
39. Di Martino, G. P., Masetti, M., Cavalli, A. & Recanatini, M. Mechanistic insights into Pn1 l peptidyl-prolyl cis-trans isomerization from umbrella sampling simulations. Proteins: Structure, Function, and Bioinformatics 82, 2941–2956 (2014).
40. Zhan, Y. A. & Vreter, F. M. The cis conformation of proline leads to weaker binding of a P53 peptide to MDM2 compared to trans. Archives of biochemistry and biophysics 575, 22–29 (2015).
41. Vöhringer-Martinez, E., Fernanda, D. & Alejandro, T.-L. How does Pn1 catalyse the cis-trans prolyl peptide bond isomerisation? a QM/MM and mean reaction force study. Journal of Physical Chemistry B 116, 12972–12979 (2012).
42. Li, G. & Cui, Q. What is so special about Arg 55 in the catalysis of cyclophilin A? insights from hybrid QM/MM simulations. Journal of the American Chemical Society 125, 15028–15038 (2003).
43. Yonezawa, Y., Nakata, K., Sakakura, K., Takada, T. & Nakamura, H. Intra- and intermolecular interaction inducing pyramidalization on both sides of a proline dipeptide during isomerization: an ab initio QM/MM molecular dynamics simulation study in explicit water. Journal of the American Chemical Society 131, 4535–4540 (2009).
44. Chen, J., Edwards, S. A., Grüter, F. & Baldauf, C. On the cis to trans isomerization of prolyl–peptide bonds under tension. Journal of Physical Chemistry B 116, 9346–9351 (2012).
45. Faller, C. E., Reilly, K. A., Hills, Jr, R. D. & Guvench, O. Peptide backbone sampling convergence with the adaptive biasing force algorithm. Journal of Physical Chemistry B 117, 518–526 (2013).
46. Yonezawa, Y., Shimoyama, H. & Nakamura, H. Multicanonical molecular dynamics simulations combined with metadynamics for the free energy landscape of a biomolecular system with high energy barriers. Chemical Physics Letters 501, 598–602 (2011).
47. Doshi, U. & Hamelberg, D. Reoptimization of the AMBER force field parameters for peptide bond (omega) torsions using accelerated molecular dynamics. Journal of Physical Chemistry B 113, 16590–16595 (2009).
48. Hamelberg, D., Shen, T. & McCammon, J. A. Phosphorylation effects on cis/trans isomerization and the backbone conformation of serine-proline motifs: accelerated molecular dynamics analysis. Journal of the American Chemical Society 127, 1969–1974 (2005).
49. Wu, M. G. & Deem, M. W. Analytical rebridging Monte Carlo: Application to cis/trans isomerization in proline-containing, cyclic peptides. Journal of Chemical Physics 111, 6625–6632 (1999).
50. Pierson, N. A., Chen, L., Valentine, S. J., Russell, D. H. & Clemmer, D. E. Number of solution states of bradykinin from ion mobility simulation analyses. Journal of the American Chemical Society 133, 13810–13813 (2011).
51. Pierson, N. A., Chen, L., Russell, D. H. & Clemmer, D. E. Cis–trans isomerizations of proline residues are key to bradykinin conformations. Journal of the American Chemical Society 135, 3186–3192 (2013).
52. Iijima, M., Anai, M., Kodama, T. & Shibasaki, Y. Epiregulin-blocking antibody inhibits epiregulin-dependent EGFR signaling. Proceedings of the National Academy of Sciences 99, 12562–12566 (2002).
53. Fischer, S., Michnick, S. & Karplus, M. A mechanism for rotamase catalysis by the FK506 binding protein (FKBP). Biochemistry 32, 13830–13837 (1993).
54. Fischer, S., Dunbrack, Jr, R. L. & Karplus, M. Cis-trans imide isomerization of the proline dipeptide. Journal of the American Chemical Society 116, 11931–11937 (1994).
55. Kado, Y. Epiregulin recognition mechanisms by anti-epiregulin antibody 9e5 structural, functional, and molecular dynamics simulation analyses. Journal of Biological Chemistry 291, 2319–2330 (2016).
56. Iijima, M., Anai, M., Kodama, T. & Shibasaki, Y. Epiregulin-blocking antibody inhibits epiregulin-dependent EGFR signaling. Biochemical and Biophysical Research Communications 489, 83–88 (2017).
57. Park, S. T., Aldape, R. A., Futer, O., DeCenzo, M. T. & Livingston, D. J. PPIase catalysis by human FK506-binding protein proceeds through a conformational twist mechanism. Journal of Biological Chemistry 267, 3316–3324 (1992).
58. Hur, S. & Bruice, T. C. The mechanism of cis–trans isomerization of prolyl peptides by cyclophilin. Journal of the American Chemical Society 124, 7303–7313 (2002).
59. Shi, T., Spain, S. M. & Rabenstein, D. L. Unexpectedly fast cis/trans isomerization of Xaa-Pro peptide bonds in disulfide-constrained cyclic peptides. Journal of the American Chemical Society 126, 796–796 (2004).
60. Rabenstein, D. L., Shi, T. & Spain, S. Intramolecular catalysis of the cis-trans isomerization of proline peptide bonds in cyclic disulfide-containing peptides. Journal of the American Chemical Society 122, 2401–2402 (2000).
61. Hamelberg, D. & McCammon, J. A. Mechanistic insight into the role of transition-state stabilization in cyclophilin A. Journal of the American Chemical Society 131, 147–152 (2008).
62. Nosé, S. A unified formulation of the constant temperature molecular dynamics methods. Journal of Chemical Physics 81, 511–519 (1984).
63. Hoover, W. G. Canonical dynamics: equilibrium phase-space distributions. Physical Review A 31, 1695 (1985).
64. Cai, H. & Wu, M. G. Grand canonical ensemble: Isolated system simulations. Physical Review A 15, 653–655 (1977).
65. Darden, T., York, D. & Pedersen, L. Particle mesh Ewald: An Nlog(N) method for ewald sums in large systems. Journal of Chemical Physics 98, 10089–10092 (1993).
66. Essmann, U. et al. A smooth particle mesh ewald method. Journal of Chemical Physics 103, 8577–8593 (1995).
67. Hess, B., Bekker, H., Berendsen, H. J. & Fraaije, J. G. et al. LINCS: a linear constraint solver for molecular simulations. Journal of Computational Chemistry 18, 1463–1472 (1997).
68. Hess, B., Kutzner, C., Van Der Spoel, D. & Lindahl, E. GROMACS 4: algorithms for highly efficient, load-balanced, and scalable molecular simulation. Journal of Chemical Theory and Computation 4, 435–447 (2008).
69. Fujitani, H., Matsuura, A., Sakai, S., Sato, H. & Tanida, Y. High-level ab initio calculations to improve protein backbone dihedral parameters. Journal of Chemical Theory and Computation 5, 1155–1165 (2009).
70. Jorgensen, W. L., Chandrasekhar, J., Madura, J. D., Impey, R. W. & Klein, M. L. Comparison of simple potential functions for simulating liquid water. Journal of Chemical Physics 79, 926–935 (1983).

Acknowledgements
This work was supported partly by the Funding Program for World-Leading Innovative Research and Development on Science and Technology (FIRST Kodama Project), HPCI strategic program field 1 (Project ID: hp120297, hp130006, hp140228, and hp150230), Innovative Drug Discovery Infrastructure through Functional Control of Biomolecular Systems, Priority Issue 1 in Post-K Supercomputer Development from MEXT (Project ID: hp160223 and hp170255).

Author Contributions
H.F. designed the study. K.S. conducted MD simulations, analysed the data and wrote the manuscript.
Additional Information

Supplementary information accompanies this paper at https://doi.org/10.1038/s41598-017-16766-8.

Competing Interests: The authors declare that they have no competing interests.

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2017